hotspot -WSS

hotspot

author：focus 2025-09-27 19:27:48 - browse：66357

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： FDA's naming rule on biosimilars has undermined competition

focus

WSS

'The Exorcist' director William Friedkin dead at 87

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

Judges halt a Biden rule offering student debt relief for those alleging colleges misled them

Scientists boost immune system in aging mice by making it youthful

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

focus

hotspot

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Food as medicine: Medically tailored meals may get standardized

Medicare proposal to cover medical devices draws a mixed reaction

Readout LOUD podcast: mifepristone case, GLP

After affirmative action ruling, medical educators look to 'holistic review'

Patient advocates debate FDA's accelerated approval process

Medicare proposal to cover medical devices draws a mixed reaction

Supreme Court mifepristone arguments center on docs' right to sue

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

entertainment

In medicine, common shorthands can shortchange care

Decaf coffee targeted by food safety group under obscure FDA rule

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Why the world’s most expensive drug might be worth the price

Why workplace violence is so common in health care

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

explore

focus

hotspot

explore